Alto Neuroscience Target of Unusually High Options Trading (NYSE:ANRO)

by · The Cerbat Gem

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors purchased 2,129 call options on the company. This is an increase of 21% compared to the average volume of 1,755 call options.

Alto Neuroscience Trading Down 63.8 %

Alto Neuroscience stock traded down $9.27 during mid-day trading on Wednesday, hitting $5.26. The company had a trading volume of 3,905,875 shares, compared to its average volume of 267,460. Alto Neuroscience has a 12 month low of $5.08 and a 12 month high of $24.00. The stock’s 50 day moving average price is $12.33 and its two-hundred day moving average price is $12.54. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. Research analysts expect that Alto Neuroscience will post -2.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ANRO. Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Robert W. Baird reduced their target price on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Wedbush cut Alto Neuroscience from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $29.00 to $4.00 in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.40.

View Our Latest Stock Analysis on Alto Neuroscience

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors have recently made changes to their positions in the company. Federated Hermes Inc. raised its stake in shares of Alto Neuroscience by 33.3% in the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after purchasing an additional 3,000 shares during the last quarter. Bowie Capital Management LLC bought a new stake in shares of Alto Neuroscience in the second quarter worth approximately $462,000. TD Asset Management Inc bought a new stake in shares of Alto Neuroscience in the second quarter worth approximately $928,000. Rhumbline Advisers bought a new position in Alto Neuroscience during the second quarter valued at approximately $113,000. Finally, Bank of New York Mellon Corp purchased a new stake in Alto Neuroscience in the second quarter worth approximately $252,000.

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

Read More